Kilts to oversee Gillette/P&G integration
This article was originally published in The Tan Sheet
Executive Summary
Gillette CEO James Kilts is stepping down as head of the blades and razors business effective July 1, P&G reports May 24. However, because "there is still a lot of work to do" regarding the Gillette integration, Kilts will continue with the company as vice chairman of P&G's board of directors until Oct. 1, a P&G spokesperson said. "Last year we planned the integration and the deal closed Oct. 1, so we're only about six months into the integration," he said. "There's still much more work ahead and [Kilts] will focus exclusively on that." P&G acquired Gillette Oral Care last year in a $57 bil. transaction (1"The Tan Sheet" Oct. 10, 2005, p. 13). Kilts will retire upon the Oct. 1 culmination of his duties, the firm noted; until then, he will continue reporting to President and CEO A.G. Lafley. The exec will be replaced by current President-Global Duracell & Braun Mark Leckie, who will assume his new position as group president-Gillette global business in July. Leckie will take on Kilts' day-to-day responsibilities, according to the firm...
You may also be interested in...
P&G Eyes Expanded Gillette Skin Care And Hair Care Offerings
Procter & Gamble will focus on growing Gillette's brand equity and product offerings in the midterm, P&G CFO Clayt Daley told analysts during an Oct. 3 conference call. P&G's $57 bil. acquisition of Gillette closed Oct. 1, one day after receiving FTC approval
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.